Semaglutide: Artificial Shortage Is Novo Nordisk’s Business Model

Image Source: Lthoms11 – CC BY-SA 4.0

In early February, drug company Novo Nordisk sued telehealth company Hims & Hers.

The complaint: Hims & Hers sells GLP-1 drugs at lower prices than Novo Nordisk. That’s the simple version.

The legalese version is that because semaglutide (the drug behind the Novo Nordisk’s “Wegovy” brand name) was removed from the US Food and Drug Administration’s “Drug Shortage List” more than a year ago, “compounding pharmacies” like Hims &...